Absolutely malmanu, those results were from AML phase 1 as a mono therapy. As the supporting data shows we could do even better as a combination therapy in phase 1b - watch this space. I think the market is asleep with regard to the SP and what treasures PTX has in the pipeline. Good for us accumulating at this low SP before the market catches on!
Ann: PTX to resume Clinical Trial of PTX-200 in Ovarian Cancer, page-10
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
